Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer

CONCLUSION: This study represents the strongest evidence to support ADT use and prolongation of adjuvant ADT to at least 18 months in localized prostate cancer in conjunction with definitive RT. The relative benefit of ADT use and adjuvant ADT prolongation was consistent irrespective of RT dose-escalation. In contrast, prolongation of neoadjuvant ADT beyond 2 months did not improve survival outcomes and should not routinely be employed.PMID:34700570 | DOI:10.1016/j.ijrobp.2021.07.046

Source: Ann Oncol - October 27, 2021 Category: Cancer & Oncology Authors: A U Kishan Y Sun T M Pisansky M Bolla A Steigler J W Denham W U Shipley H M Sandler F Y Feng D J Joseph J G Armstrong M Dunne A Zapatero T M Ma T Romero X Wang M L Steinberg W C Jackson R T Dess D E Spratt Source Type: research